A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS).

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs NP-001 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Neuraltus Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2017 Results of a post-hoc analysis assessing the prognostic significance of CRP (n=113), published in the JAMA Neurology
    • 04 Apr 2016 Secondary analyses results published in a Neuraltus Pharmaceuticals media release.
    • 20 Apr 2015 Results published in a Neuraltus Pharmaceuticals media release and online in the April 2015 issue of Neurology: Neuroimmunology & Neuroinflammation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top